Why the study?
The study was conducted to compare the safety, efficacy, prescription rates, drug defaulter, and switch-over rates of contemporary P2Y12 inhibitors in ACS patients following PCI.
Do contemporary P2Y12 inhibitors (ticagrelor or prasugrel) improve clinical outcomes compared to clopidogrel in ACS patients following PCI?
Do contemporary P2Y12 inhibitors (ticagrelor or prasugrel) improve clinical outcomes compared to clopidogrel in ACS patients following PCI?
In a resource-limited setting, clopidogrel-based DAPT showed similar clinical outcomes to ticagrelor and prasugrel with better drug adherence, supporting its safe and preferable use when supplied for free.
Answers are grounded in this paper and cite their sources.
Observational data on P2Y12 inhibitors in ACS post-PCI are hypothesis-generating; leaves open need for randomized comparisons.
Background To compare the safety, and efficacy of contemporary P2Y12 inhibitors, prescription rates, drug defaulter and switch over rates in acute coronary syndrome (ACS) patients following percutaneous coronary intervention (PCI). Methods in this prospective observational study we studied 195 ACS patients who underwent PCI in SMS Hospital, Jaipur. We compared prescription rates, bleeding, and major adverse cardiac events (MACEs: cardiac death, nonfatal myocardial infarction, or stroke) according to ticagrelor, prasugrel, or clopidogrel use. Results The prescription rates of ticagrelor, prasugrel, and clopidogrel were 29.5%, 4.3%, and 66.2% respectively. Bleeding occurred in total 6 patients (2.9%) out of which 3 patients (2.2%) in clopidogrel group, 1 patient (11.1%) in prasugrel group and 2 patients (3.2%) in ticagrelor group (p=0.29)), respectively, with higher incidence in ticagrelor and prasugrel users than in clopidogrel users but statistically not significant. After six month follow up, all-cause mortality was total 5 cases (2.4%) out of which 4 death (2.9%) occurred in clopidogrel group while 1 death (1.6%) occurred in ticagrelor group(p=0.76). no mortality was recorded in prasugrel group. Repeat myocardial infarction (Re MI) occurred in total 4 patients (1.9%) with 2 patients in clopidogrel and ticagrelor group each. A total 5 patients (2.4%) switch over to another p2y12 inhibitor, mostly from ticagrelor group(p=0.045). During this follow up period, a total of 4 patients (1.9%) were drug defaulter (0.622). Conclusions As clopidogrel based DAPT was prescribed more in our centre because of free institutional supply and found no significant difference in clinical outcomes, although slight increase in bleeding risk in ticagrelor or prasugrel based DAPT, demonstrate clopidogrel based DAPT regime can be preferably prescribed safely in our population. Drug defaulter rates in first six month following PCI are low in all groups but more switch over from ticagrelor group to other groups significantly shows importance of low cost and free institutional supply in drug adherence.
No takes yet. Share an insight, caveat, or question.
Swami et al. (2023) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: